Adenylate cyclase activity as a predictor of thyroid tumor aggressiveness
| Autor: | Qui Hua Zeng, Allan Siperstein, Orlo H. Clark, Kenneth E. Levin, Elizabeth T. Gum |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adenoma
Adult Male medicine.medical_specialty Thyrotropin Adenocarcinoma In Vitro Techniques medicine.disease_cause Cyclase Basal (phylogenetics) Thyroid-stimulating hormone Predictive Value of Tests Internal medicine medicine Carcinoma Humans Neoplasm Invasiveness Thyroid Neoplasms Thyroid neoplasm Dose-Response Relationship Drug business.industry Thyroid Receptors Thyrotropin Middle Aged medicine.disease Carcinoma Papillary Endocrinology medicine.anatomical_structure Medullary carcinoma Female Surgery business Cyclase activity Adenylyl Cyclases |
| Zdroj: | World Journal of Surgery. 12:528-532 |
| ISSN: | 1432-2323 0364-2313 |
| DOI: | 10.1007/bf01655441 |
| Popis: | Prior studies in our laboratory have shown that human thyroid neoplasms have a greater adenylate cyclase activity in response to thyroid stimulating hormone (TSH) than does the adjacent histologically normal thyroid tissue. However, there is little information relating activity of the TSH receptor-adenylate cyclase system to the type of thyroid neoplasm. Thyroid tissue from 67 patients was divided by clinical and histological criteria into 6 categories: normal (59), benign tumors (20), stage 1 carcinoma—intrathyroidal involvement only (25), stage 2 carcinomaregional lymph node involvement (6), stage 3 and 4 carcinoma—tissue invasion or distant metastasis (11), and medullary carcinoma (3). Adenylate cyclase activity in an 8,000 x g thyroid membrane preparation was determined in the basal state and when maximally stimulated with 300 mU/ml TSH. The cyclase responsiveness was the ratio of TSH stimulated adenylate cyclase activity compared to basal adenylate cyclase activity. The cyclase responsiveness by category is: normal, 2.8±0.2 (mean ± SEM); benign, 17.9±2.4; stage 1 carcinoma, 9.2±1.9; stage 2 carcinoma, 4.0±1.0; stage 3 and 4 carcinoma, 1.6±0.4; and medullary carcinoma, 1.05±0.04 (for the neoplasms,p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink